Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Dow Jones futures edge lower ahead of US Nonfarm Payrolls

Dow Jones futures edge lower ahead of US Nonfarm Payrolls

FXStreetFXStreet2026/07/02 08:57
By:FXStreet

The Dow Jones futures decline 0.15% to trade near 52,600, while S&P 500 futures fall 0.24%, trading near 7,520. Meanwhile, Nasdaq 100 futures lose 0.80% to trade near 29,850 during European trading hours on Thursday.

US stock futures declined as market participants adopted a cautious stance ahead of the highly anticipated June Nonfarm Payrolls (NFP) report. Investors are looking to the labor data for fresh insights into economic health and to gauge the Federal Reserve’s upcoming monetary policy path. This caution follows a wave of softer economic data on Wednesday, highlighted by the ADP Employment Change report, which showed private payrolls grew by just 98,000—missing Wall Street's 113,000 forecast and marking a slowdown from May's 122,000 increase. Further compounding growth concerns, the manufacturing sector showed signs of cooling as the ISM Manufacturing PMI edged lower to 53.3, missing the 54.0 consensus estimate.

Adding to the macroeconomic backdrop, Federal Reserve Chairman Kevin Warsh opted not to provide explicit guidance regarding the central bank's upcoming July policy decision during his appearance at the ECB Forum on Central Banking on Wednesday. While Warsh acknowledged that inflation remains too elevated and reiterated a firm commitment to the Fed's 2% target and institutional independence, market participants perceived his overall tone as less hawkish than anticipated.

This mix of slowing data and central bank commentary follows a losing regular trading session on Wednesday, where the S&P 500 and Dow Jones dipped 0.22% and 0.03%, respectively. The tech-heavy Nasdaq Composite felt the heaviest impact, falling 0.66% as investors began to reassess the durability of the recent AI-driven market rally. This sector rotation led to steep losses for chipmakers and memory stocks, with Micron Technology and SanDisk Corp leading the downward trend.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales